Fennec Pharmaceuticals registers $10 million of stock for public sale

Proceeds to be used for launch of drug to reduce, prevent hearing loss

By Devika Patel

Knoxville, Tenn., May 12 – Fennec Pharmaceuticals Inc. will price a public offering of common stock, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $10 million of stock.

Proceeds will be used to launch STS, a chemoprotectant being developed to reduce or prevent hearing loss, to prepare for NDA/MAA submissions for STS, for clinical studies and general corporate purposes.

The pharmaceutical company is based in Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.